Literature DB >> 25428381

Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma.

Suhua Xia1, Zhenyu Feng, Xiaowei Qi, Yuan Yin, Jianqiang Jin, Yufeng Wu, Haorong Wu, Yizhong Feng, Min Tao.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most leading causes of cancer-related death. Cancer stem cell is responsible for tumor initiation, metastasis and relapse. Sox9 is a pancreatic stem cell marker. PI3K/PTEN/Akt/mTORC is an important signal for maintaining stem cells. The purpose of this study is to determine the expression pattern of Sox9 and p-Akt in human PDAC and its correlation with prognosis. Immunohistochemical analysis was used to explore the expression of Sox9 and p-Akt in 88 human PDAC patients. The Pearson's test was used to compare the clinicopathological parameters between negative and positive expressors. The Pearson's correlation analysis was used to explore the relationship between Sox9 and p-Akt expression. Kaplan-Meier's method and Cox regression analysis were used to analyze patients' survival. The results showed that Sox9 and p-Akt overactivated in PDAC (p = 0.011, p = 0.008). Sox9-positive expression is significantly associated with distant metastasis (p = 0.046). p-Akt-positive expression is significantly associated with distant metastasis (p = 0.000), TNM stage (0.001) and PCNA expression (p = 0.000). Sox9 expression is positively correlated with p-Akt expression (r = 0.314, p = 0.003). In 54 patients with survival information, both Sox9- and p-Akt-positive expressions are associated with unfavorable prognosis (p = 0.002, p = 0.000). Sox9 and p-Akt double-positive expressor showed much poorer prognosis (p = 0.000). Cox regression analysis showed that Sox9- or p-Akt-positive expression and LN metastasis were independent prognostic factors. This study provides the first evidence that Sox9 and p-Akt are both relevant to distant metastasis and proliferation. Our data suggest the potential of Sox9 and p-Akt as prognostic biomarkers for PDAC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25428381     DOI: 10.1007/s12032-014-0358-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  34 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

2.  Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells.

Authors:  Yuanyan Wei; Yizhou Jiang; Fei Zou; Yingchao Liu; Shanshan Wang; Nuo Xu; Wenlong Xu; Chunhong Cui; Yang Xing; Ying Liu; Benjin Cao; Chanjuan Liu; Guoqiang Wu; Hong Ao; Xiaobiao Zhang; Jianhai Jiang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-08       Impact factor: 11.205

3.  Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.

Authors:  Ioanna G Maroulakou; William Oemler; Stephen P Naber; Philip N Tsichlis
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

4.  SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms.

Authors:  Stuti Shroff; Asif Rashid; Hua Wang; Matthew H Katz; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Hum Pathol       Date:  2013-10-19       Impact factor: 3.466

5.  PI3K/AKT regulates aggrecan gene expression by modulating Sox9 expression and activity in nucleus pulposus cells of the intervertebral disc.

Authors:  Chin-Chang Cheng; Yoshiyasu Uchiyama; Akihiko Hiyama; Sachin Gajghate; Irving M Shapiro; Makarand V Risbud
Journal:  J Cell Physiol       Date:  2009-12       Impact factor: 6.384

6.  Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma.

Authors:  Janel L Kopp; Guido von Figura; Erin Mayes; Fen-Fen Liu; Claire L Dubois; John P Morris; Fong Cheng Pan; Haruhiko Akiyama; Christopher V E Wright; Kristin Jensen; Matthias Hebrok; Maike Sander
Journal:  Cancer Cell       Date:  2012-11-29       Impact factor: 31.743

7.  FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

Authors:  Huadong Pei; Liang Li; Brooke L Fridley; Gregory D Jenkins; Krishna R Kalari; Wilma Lingle; Gloria Petersen; Zhenkun Lou; Liewei Wang
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

8.  A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics.

Authors:  Y H Wang; F Li; B Luo; X H Wang; H C Sun; S Liu; Y Q Cui; X X Xu
Journal:  Neoplasma       Date:  2009       Impact factor: 2.575

9.  Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9.

Authors:  T Wagner; J Wirth; J Meyer; B Zabel; M Held; J Zimmer; J Pasantes; F D Bricarelli; J Keutel; E Hustert; U Wolf; N Tommerup; W Schempp; G Scherer
Journal:  Cell       Date:  1994-12-16       Impact factor: 41.582

10.  Novel SOX9 expression during human pancreas development correlates to abnormalities in Campomelic dysplasia.

Authors:  K Piper; S G Ball; J W Keeling; S Mansoor; D I Wilson; N A Hanley
Journal:  Mech Dev       Date:  2002-08       Impact factor: 1.882

View more
  17 in total

1.  PEBP4 promoted the growth and migration of cancer cells in pancreatic ductal adenocarcinoma.

Authors:  Dexiang Zhang; Yuedi Dai; Yuankun Cai; Tao Suo; Han Liu; Yueqi Wang; Zhijian Cheng; Houbao Liu
Journal:  Tumour Biol       Date:  2015-08-27

2.  [Effect of down-regulation of sex determining region Y-box 9 on epithelial mesenchymal transition and cloning of oral squamous carcinoma cells].

Authors:  Wen-Li Yang; Ming-Lei Sun; Peng Zhang; Wei-Wei Yu; Hai-Xia Zhou; Qiang Sun
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2019-02-01

3.  ZNF281 Promotes Growth and Invasion of Pancreatic Cancer Cells by Activating Wnt/β-Catenin Signaling.

Authors:  Yu Qian; Jingyi Li; Suhua Xia
Journal:  Dig Dis Sci       Date:  2017-05-18       Impact factor: 3.199

4.  Hypoxia-induced lncRNA CASC9 enhances glycolysis and the epithelial-mesenchymal transition of pancreatic cancer by a positive feedback loop with AKT/HIF-1α signaling.

Authors:  Zhengle Zhang; Erhu Fang; Yuping Rong; Han Han; Qiong Gong; Yingyan Xiao; Hehe Li; Pei Mei; Hanjun Li; Zhongchao Zhu; Zhigang Tang; Jing Tao
Journal:  Am J Cancer Res       Date:  2021-01-01       Impact factor: 6.166

5.  SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.

Authors:  H Zhou; Y Qin; S Ji; J Ling; J Fu; Z Zhuang; X Fan; L Song; X Yu; P J Chiao
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

6.  Expression of SOX9 Is Related to Prognosis in Patients with Oesophageal Squamous Cell Carcinoma.

Authors:  Naotomo Higo; Hiroshi Okumura; Yasuto Uchikado; Itaru Omoto; Ken Sasaki; Yoshiaki Kita; Desaki Ryosuke; Masahiro Noda; Tetsuhiro Owaki; Sumiya Ishigami; Shoji Natsugoe
Journal:  In Vivo       Date:  2018 Jul-Aug       Impact factor: 2.155

7.  MicroRNA-494 inhibits cell proliferation and invasion of chondrosarcoma cells in vivo and in vitro by directly targeting SOX9.

Authors:  Jingyuan Li; Lijuan Wang; Zongzhi Liu; Chao Zu; Fanfan Xing; Pei Yang; Yongkang Yang; Xiaoqian Dang; Kunzheng Wang
Journal:  Oncotarget       Date:  2015-09-22

8.  Inhibitory effect of Ginkgol C17:1 on the biological behavior of tumor cells.

Authors:  Yueying Li; Jun Liu; Yali Liu; Xiaoming Yang; Bingzhong Huang; Min Chen
Journal:  Oncol Lett       Date:  2017-02-01       Impact factor: 2.967

9.  Upregulation of sex-determining region Y-box 9 (SOX9) promotes cell proliferation and tumorigenicity in esophageal squamous cell carcinoma.

Authors:  Yingcai Hong; Wen Chen; Xiaojun Du; Huiwen Ning; Huaisheng Chen; Ruiqing Shi; Shaolin Lin; Rongyu Xu; Jinrong Zhu; Shu Wu; Haiyu Zhou
Journal:  Oncotarget       Date:  2015-10-13

10.  Construction of a prognostic prediction system for pancreatic ductal adenocarcinoma to investigate the key prognostic genes.

Authors:  Bingli Zheng; Jie Peng; Ablikim Mollayup; Ahmat Bakri; Lei Guo; Jianjiang Zheng; Hui Xu
Journal:  Mol Med Rep       Date:  2017-10-20       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.